Virinchi Limited has successfully completed the allotment of 13,15,715 equity shares following the conversion of warrants issued on preferential basis to its promoter group. The company announced this development on February 24, 2026, in compliance with regulatory disclosure requirements under SEBI listing obligations.

SEBI Regulatory Filing by Vivo Bio Tech

Vivo Bio Tech Limited has filed a comprehensive disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the warrant conversion. The filing, submitted on February 25, 2026, provides detailed information about the substantial acquisition and its impact on shareholding patterns.

Share Allotment and Acquisition Details

The allotment involved equity shares of Rs.10 each issued at a premium price of Rs.28 per share, which includes a premium of Rs.18 per share. The entire allocation was made to Vivo Bio Tech Limited, classified as a promoter group entity. The conversion was executed upon receipt of the requisite application money from the allottee.

Shareholding Pattern Changes

The SEBI filing reveals significant changes in Vivo Bio Tech's shareholding pattern in Virinchi Limited. Before the acquisition, Vivo Bio Tech held 37,84,285 shares carrying voting rights, representing 3.48% of total share capital. Post-acquisition, their holding increased to 51,00,000 shares, representing 4.69% of total share capital.

Capital Structure Impact

Following this allotment, Virinchi Limited's capital structure has undergone significant changes. The company's issued and subscribed share capital has increased substantially, reflecting the successful conversion of the preferential warrants into equity shares.

The conversion strengthens the promoter group's stake in the company while providing additional capital resources to Virinchi Limited for its business operations and growth initiatives. The regulatory compliance ensures full transparency in substantial acquisition reporting as mandated by SEBI regulations.

Virinchi Limited has formally disclosed the detailed voting results and scrutinizer's report for its postal ballot conducted on February 23, 2026, in compliance with Regulation 30 and 44(3) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company informed both BSE Limited and National Stock Exchange of India Limited about the successful approval of two special resolutions related to its wholly-owned subsidiary operations.

Approved Special Resolutions

Shareholders approved two critical special resolutions through the postal ballot process:

Both resolutions involved promoter group interest and required enhanced shareholder approval thresholds as special resolutions.

Comprehensive Voting Results

The postal ballot witnessed strong shareholder support with detailed participation metrics:

The voting was conducted exclusively through e-voting facility provided by Central Depository Services Limited (CDSL). Notably, promoter and promoter group shareholders, holding 38505538 shares, abstained from voting on both resolutions due to their interest in the matters.

Scrutinizer Report and Process Details

CS Vinay Babu Gade, Company Secretary in Practice (ACS No. 20592), served as the appointed scrutinizer and submitted his comprehensive report on February 23, 2026:

Member-wise Voting Analysis

The scrutinizer's report provided detailed member participation statistics:

No invalid votes were recorded for either resolution, indicating proper compliance with voting procedures.

Regulatory Compliance and Communication

The postal ballot process was conducted in strict compliance with Section 108 and 109 of the Companies Act, 2013, and Regulation 44 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Company Secretary K Ravindranath Tagore (M.No. A18894) signed the disclosure letter, confirming that voting results and scrutinizer's report would be made available on the company website at www.virinchi.com .

The successful approval of both resolutions enables Virinchi Limited to proceed with strategic initiatives involving Virinchi Health Care Private Limited, including facilitating related party investment and implementing the convertible equity warrants structure for enhanced subsidiary operations.